CoChat

Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023

Open access
Xiong, Si, Gou, Ruoyu, Liang, Xudong, Wu, Hao, Qin, Shuitao, Li, Bing, Luo, Changjun, Chen, Junan · 2024 · Diabetes Therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have attracted much attention because of their significant hypoglycemic and weight-loss effects. Previous preparations can only be subcutaneously injected. Oral administration of GLP-1RAs semaglutide helps to broaden treatment options, but its safety in the real world still needs to be observed. This study is based on FDA adverse event reporting system (FAERS) database to mine adverse drug events (ADE) of oral semaglutide, and provide references for the clinical safe use of this drug. METHODS: To analyze the signal quality of oral semaglutide, which is a drug used in the FAERS database from the third quarter of 2019 to the third quarter of 2023, we collected ADE data and performed data mining by using disproportionate analysis. Then, we standardized the data and used a variety of signal-quantification techniques, including reported odds ratio (ROR), proportional reporting ratio (PRR), Bayesian belief propagation neural network (BCPNN), and multiple empirical Bayesian gamma Poisson contractions (MGPS), for further analysis. RESULTS: We screened 2398 reports on the use of semaglutide tablets, involving a total of 5653 ADE. These reports were mainly submitted by consumers, and the reporting country was mainly the United States. A total of 23 system organ classes (SOC) and 93 preferred terms (PT) were mined for the signals of semaglutide tablets. The three most common SOC were gastrointestinal disorders, general disorders and administration site conditions, and investigations. At the PT level, metabolism and nutrition disorders exhibit the highest number of signals, with the top three being thyroid cyst, acute cholecystitis, and ketosis. Gastrointestinal disorders rank second, primarily involving eructation, pancreatitis, impaired gastric emptying, and regurgitation. In addition, vith nerve paralysis occurs and the signal intensity is high. CONCLUSIONS: Our study provides a deeper and broader understanding of the safety of oral semaglutide. The results of the ROR, PRR, BCPNN, and MGPS algorithms exhibit high consistency, with metabolism and nutrition-related disorders having the highest number of signals. The conclusions align with the technical specifications of the product. Notably, other unexpected effects are reported, including acute cholecystitis, paralysis of the abducens nerve, and positional vertigo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-024-01594-7

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram of selecting semaglutide-associated adverse events (AEs) from the FDA adverse event reporting system (FAERS) database. ROR reported odds ratio, PRR proportional reporting ratio, BCPNN Bayesian belief propagation neural network, MGPS multiple empirical Bayesian gamma Poisson contractions
Fig. 1 Flow diagram of selecting semaglutide-associated adverse events (AEs) from the FDA adverse event reporting system (FAERS) database. ROR reported odds ratio, PRR proportional reporting ratio, BCPNN Bayesian belief propagation neural network, MGPS multiple empirical Bayesian gamma Poisson contractionsCC BY-NC · PubMed Central
Fig. 2 Bar graph of ADE signal intensity of smeglutide tablets at SOC level in FAERS database. ADE adverse drug events, SOC system organ classes, FAERS FDA adverse event reporting system
Fig. 2 Bar graph of ADE signal intensity of smeglutide tablets at SOC level in FAERS database. ADE adverse drug events, SOC system organ classes, FAERS FDA adverse event reporting systemCC BY-NC · PubMed Central
Fig. 3 Forest plot of the top 30 signal strength of adverse events of Semaglutide ranked by ROR at the PTs level in FAERS database. ROR reported odds ratio, PT preferred terms, FAERS FDA adverse event reporting system, CI confidence interval
Fig. 3 Forest plot of the top 30 signal strength of adverse events of Semaglutide ranked by ROR at the PTs level in FAERS database. ROR reported odds ratio, PT preferred terms, FAERS FDA adverse event reporting system, CI confidence intervalCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - PubMed. https://pubmed.ncbi.nlm.nih.gov/36148880/. Accessed 3 Mar 2024. PMC10008140 36148880
  2. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial - PubMed. https://pubmed.ncbi.nlm.nih.gov/29049653/. PMC5817971 29049653
  3. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes - PubMed. https://pubmed.ncbi.nlm.nih.gov/31186300/. Accessed 3 Mar 2024. 31186300

Cited by

See all 30

Metadata

Authors
Xiong, S., Gou, R., Liang, X., Wu, H., Qin, S., Li, B., Luo, C., & Chen, J.
Affiliations
  • Guangxi Medical University (CN)
  • Ningxia Medical University (CN)
Corresponding author
  • Luo, Changjun
  • Chen, Junan
Venue
Diabetes Therapy
Published
2024-05-22
Volume
15
Issue
8
Pages
1717-1733
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4398211111
Cited by
26
References
29
Citations by year
2026: 10 · 2025: 14 · 2024: 2
FWCI
6.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
the National Natural Science Foundation of China (No.82360052)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, GLP-1 receptor agonists, adverse drug reactions, drug safety, adverse event signals, thyroid cysts, acute cholecystitis, ketosis, pancreatitis, impaired gastric emptying, abducens nerve palsy, positional vertigo, drug-induced hypoglycemia, drug-induced weight loss, FDA Adverse Event Reporting System, disproportionality analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.